Author:
Zhou Gang,Niu Lizhi,Chiu David,He Lihua,Xu Kecheng
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Biotechnology,Bioengineering,Applied Microbiology and Biotechnology
Reference21 articles.
1. Banfi G, Bravi S, Ardemagni A (2000) Quantitative analysis of CA125 cytosolic contest in patients with pancreatic cancer. Int J Biol Markers 18:284
2. Carpelan M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G (2005) Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 54:385–387
3. Eickhoff A, Martin W, Hartmann D (2006) A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma. Br J Cancer 94:1572–1574
4. Gage AA, Baust JG (2007) Cryosurgery for tumors. J Am Coll Surg 205:342–356
5. Giannini E, Borro P, Botta F (2001) Cholestasis is the main determinant of abnormal CA199 levels in patients with pancreatic cancer. Int J Biol Markers 15:126–129